Linked Life Data

11320857

Source:http://linkedlifedata.com/resource/pubmed/id/11320857

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2001-4-25
pubmed:abstractText
Erythropoietin (EPO) is a glycoprotein synthesized by the kidney, which has a stimulating effect on bone marrow erythroid precursors. It has been identified many years ago, but its clinical use has been developed only since 1985 with the introduction of recombinant molecle (rHuEPO). In the past decade, rHuEPO has been employed in neoplastic as well as in chronic inflammatory diseases associated with anemia, that recognizes a multifactorial pathogenesis: defective endogenous EPO production, impaired erythroid proliferation due to excessive release of inflammatory cytokines, intrinsic abnormalities of erythroid precursors, reticulo-endothelial blockage with reduced erythroid uptake of iron. Anemia of neoplastic diseases, moreover, may be induced or worsened by marrow toxicity of chemotherapy. The efficacy of rHuEPO in these conditions is still unclear.
pubmed:language
ita
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0034-1193
pubmed:author
pubmed:issnType
Print
pubmed:volume
92
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
223-33
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
[Use of erythropoietin in hematologic oncology].
pubmed:affiliation
Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma.
pubmed:publicationType
Journal Article, English Abstract, Review